FORT WASHINGTON, Pa., April 6 /PRNewswire/ -- Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative drugs, announced today the appointment of Donald Hayden as Chairman of Vitae’s Board of Directors. Mr. Hayden spent nearly 25 years with Bristol-Myers Squibb, most recently reporting to the CEO as President, Americas, where he led a group consisting of two major pharmaceutical units and two healthcare businesses with combined annual sales exceeding $10 billion, and BMS’s global manufacturing organization.
“We are thrilled to add Don to Vitae Pharmaceuticals’ leadership team, as we continue to advance multiple product candidates across key therapeutic areas,” said Jeffrey Hatfield, CEO of Vitae Pharmaceuticals. “Don’s proven track record of building and growing successful products, businesses and organizations will be of tremendous value to Vitae as we continue to accelerate our success. Further, his deep knowledge across a diverse array of therapeutic areas, including cardiovascular disease and oncology, will be a strategic resource for us as we grow.”
“I am very excited to have the opportunity to work with Jeff and the strong, talented team at Vitae to help build the company and create a high-growth business that delivers innovative products in areas of high unmet medical need,” said Don Hayden, Board Chairman.
Mr. Hayden is a seasoned global pharmaceutical and healthcare executive with an extensive history of successful business transformation, innovative strategy development and delivery of outstanding operating results. He has a proven track record of building and growing successful products, businesses and organizations, with an experience base that includes: broad-based business development, managing major alliances, building exceptional leadership teams, and developing a customer-focused culture of high performance with the highest integrity. He holds a Master’s in Business Administration from Indiana University and a Bachelor of Arts from Harvard University.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated to the discovery and development of innovative drugs by advancing its pipeline of product candidates. Vitae is uniquely able to discover innovative compounds by accelerating and enhancing the drug discovery skills and experience of proven drug hunters with world-class, proprietary drug design technologies developed in collaboration with Intel Corporation. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors and is headquartered in Fort Washington, Pennsylvania. For additional information, please visit the company’s website, http://www.vitaepharma.com.
Vitae Pharmaceuticals, Inc.
CONTACT: Kathryn Morris of KMorris PR, +1-845-635-9828, for VitaePharmaceuticals
Web site: http://www.vitaepharma.com/
